#USA #Barcelona #Gout Treatment #SAP-001 #Shanton Pharma

Shanton Pharma to Present Data at EULAR 2025

Shanton Pharma, a biotech company situated in Singapore, is set to present pivotal topline data from its phase 2b clinical study on SAP-001, a novel treatment designed specifically for patients suffering from refractory gout. This significant event will take place during the highly-anticipated EULAR (European Alliance of Associations for Rheumatology) Congress, held in Barcelona from June 11 to June 14, 2025. The exact presentation of the findings is scheduled for June 14.

The phase 2b study aims to address the needs of patients who are unresponsive to existing treatment options. Shanton's lead investigational compound, SAP-001, is positioned as a revolutionary therapy that targets a specific renal transporter—an innovation that could transform how gout is managed, especially for those living with chronic symptoms.

During the congress, attendees can expect to hear Dr. Wenfeng Miao, Shanton's Chief Medical Officer, share insights on the clinical data. Dr. Miao stated, “We are excited to present our phase 2b topline data to the global rheumatology community at EULAR. We know that medical practitioners have long been looking for a new mechanism in gout management for their difficult-to-treat patients.” He further emphasized the potential of SAP-001 to fill a critical gap for patients who either do not respond to or cannot tolerate conventional urate-lowering therapies, which are typically utilized in standard treatment protocols.

SAP-001 stands as a testament to Shanton's commitment to addressing unmet medical needs related to hyperuricemia and uric acid-related conditions. The company was founded in 2016 by a team of seasoned pharmaceutical entrepreneurs who share a vision of enhancing treatment landscapes for challenging illnesses. With its headquarters in Singapore and research activities extending to the United States and China, Shanton is fully equipped for extensive clinical development.

The company's research has indicated that SAP-001 boasts robust efficacy and a favorable safety profile, derived from its unique mechanism of action. In earlier Phase 1 and Phase 2a studies, SAP-001 exhibited superior results compared to existing treatments, particularly in patients demonstrating hyperuricemia resistant to traditional xanthine oxidase inhibitors, a commonly prescribed medication for gout management.

As the EULAR Congress gathers experts and thought leaders in rheumatology, Shanton Pharma's presentation is expected to leave a lasting impact that may drive advancements in how refractory gout is treated. This year’s congress theme aligns with fostering innovation in patient care, making Shanton’s presence particularly poignant.

For stakeholders and interested professionals wishing to learn more about this promising treatment option, additional information can be found on Shanton Pharma’s official website, which contains comprehensive details about their ongoing clinical trials and mission to reform gout treatments.

As a reminder, Shanton Pharma will also be part of the broader narrative at EULAR, showcasing its dedication to pioneering solutions that address the complexities of chronic illnesses like gout. This congress not only serves as a platform for knowledge exchange but also reinforces the importance of innovation in combating debilitating health conditions.

To stay updated on Shanton Pharma’s latest news and developments, please visit their website or follow their official communications.